Search

Your search keyword '"Doggett J"' showing total 10 results
Start Over Author "Doggett J" Journal antimicrobial agents and chemotherapy
10 results on '"Doggett J"'

1. Effective Therapy Targeting Cytochrome bc 1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection

Author

Chiu, Joy E., primary, Renard, Isaline, additional, Pal, Anasuya C., additional, Singh, Pallavi, additional, Vydyam, Pratap, additional, Thekkiniath, Jose, additional, Kumar, Madelyn, additional, Gihaz, Shalev, additional, Pou, Sovitj, additional, Winter, Rolf W., additional, Dodean, Rozalia, additional, Frueh, Lisa, additional, Nilsen, Aaron C., additional, Riscoe, Michael K., additional, Doggett, J. Stone, additional, and Mamoun, Choukri Ben, additional

Published
2021
Full Text
View/download PDF

7. Effective Therapy Targeting Cytochrome bc1Prevents BabesiaErythrocytic Development and Protects from Lethal Infection

Author

Chiu, Joy E., Renard, Isaline, Pal, Anasuya C., Singh, Pallavi, Vydyam, Pratap, Thekkiniath, Jose, Kumar, Madelyn, Gihaz, Shalev, Pou, Sovitj, Winter, Rolf W., Dodean, Rozalia, Frueh, Lisa, Nilsen, Aaron C., Riscoe, Michael K., Doggett, J. Stone, and Mamoun, Choukri Ben

Abstract

An effective strategy to control blood-borne diseases and prevent outbreak recrudescence involves targeting conserved metabolic processes that are essential for pathogen viability. One such target for Plasmodiumand Babesia, the infectious agents of malaria and babesiosis, respectively, is the mitochondrial cytochrome bc1protein complex, which can be inhibited by endochin-like quinolones (ELQ) and atovaquone.

Published
2021
Full Text
View/download PDF

9. Genetic Evidence for Cytochrome bQiSite Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii

Author

Alday, P. Holland, Bruzual, Igor, Nilsen, Aaron, Pou, Sovitj, Winter, Rolf, Ben Mamoun, Choukri, Riscoe, Michael K., and Doggett, J. Stone

Abstract

ABSTRACTToxoplasma gondiiis an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc1complex Qisite for ELQ sensitivity, the mechanism of action of ELQs against T. gondiiand the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondiiclones resistant to ELQ-316. A T. gondiistrain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Qisite inhibitor. These findings provide further evidence for ELQ Qisite inhibition in T. gondiiand greater insight into the interactions of Qisite inhibitors with the apicomplexan cytochrome bc1complex.

Published
2016
Full Text
View/download PDF

10. Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii.

Author

Alday PH, Bruzual I, Nilsen A, Pou S, Winter R, Ben Mamoun C, Riscoe MK, and Doggett JS

Subjects
Antimycin A pharmacology, Mitochondria drug effects, Mitochondria metabolism, Toxoplasma metabolism, Toxoplasmosis parasitology, Antimycin A analogs & derivatives, Cytochromes b genetics, Quinolones pharmacology, Toxoplasma drug effects
Abstract

Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc 1 complex Q i site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Q i site inhibitor. These findings provide further evidence for ELQ Q i site inhibition in T. gondii and greater insight into the interactions of Q i site inhibitors with the apicomplexan cytochrome bc 1 complex., (Copyright © 2017 American Society for Microbiology.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results